Cim LLC Has $1.70 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Cim LLC grew its stake in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 6.0% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 9,807 shares of the company’s stock after purchasing an additional 556 shares during the quarter. Cim LLC’s holdings in Johnson & Johnson were worth $1,697,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Price T Rowe Associates Inc. MD lifted its stake in Johnson & Johnson by 18.9% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 24,622,795 shares of the company’s stock valued at $4,370,793,000 after purchasing an additional 3,912,430 shares during the last quarter. FMR LLC lifted its position in shares of Johnson & Johnson by 20.8% in the second quarter. FMR LLC now owns 18,725,049 shares of the company’s stock valued at $3,323,883,000 after buying an additional 3,229,032 shares during the last quarter. GQG Partners LLC boosted its stake in shares of Johnson & Johnson by 64.4% during the 1st quarter. GQG Partners LLC now owns 6,501,761 shares of the company’s stock worth $1,151,931,000 after acquiring an additional 2,547,378 shares during the period. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main increased its holdings in shares of Johnson & Johnson by 52.2% during the 2nd quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 6,102,999 shares of the company’s stock worth $1,083,329,000 after acquiring an additional 2,093,392 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership raised its stake in Johnson & Johnson by 37.2% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 6,653,610 shares of the company’s stock valued at $1,179,219,000 after acquiring an additional 1,805,632 shares during the period. Institutional investors own 67.94% of the company’s stock.

Analyst Upgrades and Downgrades

JNJ has been the topic of several research reports. SVB Leerink dropped their price objective on shares of Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating on the stock in a research report on Friday, January 20th. Citigroup raised their price objective on shares of Johnson & Johnson from $198.00 to $205.00 and gave the stock a “buy” rating in a research report on Monday, December 12th. StockNews.com began coverage on Johnson & Johnson in a research report on Wednesday, October 12th. They issued a “strong-buy” rating on the stock. Credit Suisse Group initiated coverage on Johnson & Johnson in a report on Thursday, November 17th. They set a “neutral” rating and a $170.00 price target for the company. Finally, Atlantic Securities decreased their price objective on Johnson & Johnson from $165.00 to $160.00 and set a “neutral” rating on the stock in a report on Wednesday, October 19th. Seven research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Johnson & Johnson has a consensus rating of “Moderate Buy” and an average target price of $181.75.

Insider Activity

In related news, VP Thibaut Mongon sold 35,246 shares of the firm’s stock in a transaction dated Friday, November 4th. The stock was sold at an average price of $171.18, for a total value of $6,033,410.28. Following the sale, the vice president now directly owns 40,133 shares of the company’s stock, valued at $6,869,966.94. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In related news, EVP Ashley Mcevoy sold 73,323 shares of the stock in a transaction that occurred on Wednesday, November 30th. The shares were sold at an average price of $175.47, for a total value of $12,865,986.81. Following the completion of the transaction, the executive vice president now owns 41,813 shares of the company’s stock, valued at approximately $7,336,927.11. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, VP Thibaut Mongon sold 35,246 shares of the business’s stock in a transaction on Friday, November 4th. The stock was sold at an average price of $171.18, for a total transaction of $6,033,410.28. Following the sale, the vice president now directly owns 40,133 shares in the company, valued at approximately $6,869,966.94. The disclosure for this sale can be found here. In the last quarter, insiders have sold 233,611 shares of company stock worth $40,960,735. Insiders own 0.35% of the company’s stock.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $168.31 on Wednesday. The stock has a market capitalization of $440.04 billion, a P/E ratio of 23.44, a PEG ratio of 3.21 and a beta of 0.56. The stock’s fifty day moving average is $175.98 and its 200 day moving average is $171.06. Johnson & Johnson has a 52 week low of $155.72 and a 52 week high of $186.69. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.18 and a current ratio of 1.43.

Johnson & Johnson (NYSE:JNJGet Rating) last released its earnings results on Tuesday, January 24th. The company reported $2.35 EPS for the quarter, beating the consensus estimate of $2.23 by $0.12. Johnson & Johnson had a net margin of 19.95% and a return on equity of 35.37%. The firm had revenue of $23.71 billion for the quarter, compared to analyst estimates of $23.90 billion. During the same period last year, the firm earned $2.13 EPS. The business’s quarterly revenue was down 4.4% compared to the same quarter last year. Sell-side analysts forecast that Johnson & Johnson will post 10.04 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 7th. Shareholders of record on Tuesday, February 21st will be issued a $1.13 dividend. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.69%. The ex-dividend date of this dividend is Friday, February 17th. Johnson & Johnson’s dividend payout ratio is presently 62.95%.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

Featured Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.